Skip to main
XGN

Exagen Inc (XGN) Stock Forecast & Price Target

Exagen Inc (XGN) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Exagen Inc has demonstrated notable financial performance, with a 19% year-over-year revenue increase over the past nine months, driven by balanced growth in average selling prices (ASPs) and testing volumes. The company's ASPs have risen to $441 per test, reflecting a 9.2% increase year-over-year, which, despite current challenges, indicates positive momentum towards sustained financial growth. Additionally, Exagen has shown effective operational management, evident in its substantial share price appreciation of 133% year-to-date and a strategic expansion plan to increase its sales territories, further positioning the company for ongoing growth in the competitive diagnostics market.

Bears say

Exagen Inc. reported a top-line revenue of $17.2 million for the second quarter of 2025, which was a positive indicator, but the bottom-line results included a GAAP EPS loss of $0.21, falling short of the consensus estimate and reflecting ongoing financial challenges. The company has undergone significant cost-cutting measures, including a 42 full-time equivalent reduction across various departments, which raises concerns about its growth potential and ability to maintain sales momentum. Furthermore, despite having a backlog of $3.5 million, revenue is expected to remain inconsistent, leading to potential volatility in future earnings and reinforcing a negative outlook on the company's stock performance.

Exagen Inc (XGN) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exagen Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exagen Inc (XGN) Forecast

Analysts have given Exagen Inc (XGN) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Exagen Inc (XGN) has a Strong Buy consensus rating as of Dec 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exagen Inc (XGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.